gemcitabine-oxaliplatin regimen

12/01/2007 - "This study was to analyze the efficacy of GEMOX regimen on advanced pancreatic cancer, and observe the adverse events. "
08/01/2007 - "Analyses of the available evidences suggest GEMOX regimen is promising as the first-line therapy for advanced pancreatic cancer, which encourages further clinical trials."
12/01/2007 - "But in China, the use of GEMOX regimen for advance pancreatic cancer has seldom been reported. "
08/01/2007 - "This meta-analysis included all randomized evidences to compare GEMOX regimen with GEM alone with respect to overall survival rate and adverse events in patients with advanced pancreatic cancer. "
08/01/2007 - "This study was to evaluate the efficacy of GEM of fixed-dose rate infusion plus oxaliplatin (GEMOX regimen) as first-line therapy for advanced pancreatic cancer by meta-analysis. "

01/01/2013 - "GEMOX regimen is very effective to treat advanced ovarian cancer, with low toxicity, good tolerance and improved life quality in patients."
01/01/2013 - "Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer."
01/01/2008 - "The GEMOX regimen has moderate activity in both platinum-sensitive and resistant ovarian cancer and a toxicity profile that can be significant and therefore requires careful monitoring."
01/01/2008 - "The aim of this study was to evaluate the safety and activity of a gemcitabine-oxaliplatin combination (GEMOX) regimen in pretreated patients with advanced ovarian cancer. "
01/01/2013 - "To investigate the effectiveness and adverse effects of gemcitabine by fixed-dose rate infusion plus oxaliplatin (GEMOX regimen) as second-line therapy for advanced ovarian cancer. "

03/01/2010 - "Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience."
02/05/2019 - "Coxproportional analysis showed that tumor diameter and Ann Arbor stage were signifcant factors affecting overall survival(P =0.016,0.025).Adverse reactions caused by the P-Gemox chemotherapy regimen are mild and more common in grades I to II. Conclusion: The P-Gemox regimen combined with radiotherapy may be a promising option in the treatment of newly-diagnosed ENKTL due to its high efficacy yet low toxicity, and clinical stage has an important effect on CR and OS."
10/01/2010 - "By reviewing the literature we found that the Gemox regimen seems to be active in the treatment of various kinds of tumors and is well tolerated. "
01/01/2006 - "The interesting tumor growth control rate and the favorable toxicity profile of the GEMOX regimen in pretreated patients with advanced CRC strongly suggest that this regimen may provide an alternative therapeutic option for this group of patients."
12/01/2007 - "Clinical data of 32 chemonaive patients with stage III-IV pancreatic cancer, treated with GEMOX regimen [intravenous injection of gemcitabine (1 000 mg/m(2)) at Day 1 and Day 8, and intravenous injection of oxaliplatin (85-130 mg/m(2)) at Day 1; repeated every 21 days] at Cancer Center of Sun Yat-sen University from Feb. "

10/01/2017 - "To explore the clinical efficacy of GEMOX regimen on patients with refractory non-hodgkin's lymphoma. "
10/01/2017 - "[Efficacy Analysis of GEMOX Regimen for Treatment of Refractory Non-Hodgkin's Lymphoma]."
04/01/2015 - "A total of 61 patients with relapse and refractory non-Hodgkin's lymphoma (NHL) treated with chanotherapy of GEMOX regimen from 2010 Jannary -2013 year were selected, and their clinical data were collected, and the short-term efficacy, toxic effects and short-term survival were analyzed. "
10/01/2017 - "The efficacy of GEMOX regimen for refractory non-Hodgkin's lymphoma has been confirmed to be good, it has distinct clinical curative effect, it can prolong the progression-free survival time in patients with B cell lymphoma, specially for III-IV stages. "

05/17/2016 - "Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma."